WO2017141137A1 - Composition et forme posologique pour réduction de la charge virale en vih - Google Patents

Composition et forme posologique pour réduction de la charge virale en vih Download PDF

Info

Publication number
WO2017141137A1
WO2017141137A1 PCT/IB2017/050676 IB2017050676W WO2017141137A1 WO 2017141137 A1 WO2017141137 A1 WO 2017141137A1 IB 2017050676 W IB2017050676 W IB 2017050676W WO 2017141137 A1 WO2017141137 A1 WO 2017141137A1
Authority
WO
WIPO (PCT)
Prior art keywords
mebendazole
dosage form
hiv
composition
reducing
Prior art date
Application number
PCT/IB2017/050676
Other languages
English (en)
Inventor
Shoket Latief
Misree Khan SARGURO
Original Assignee
Shoket Latief
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shoket Latief filed Critical Shoket Latief
Publication of WO2017141137A1 publication Critical patent/WO2017141137A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • THIS INVENTION relates to a composition for use in a method for reducing an Human Immunodeficiency Virus (HIV) viral load in a subject infected with HIV. It relates also to a dosage form and pharmaceutical composition for use in a method of reducing an HIV viral load in a subject infected with HIV.
  • HIV Human Immunodeficiency Virus
  • compositions for use in a method of reducing an HIV viral load in a subject infected with HIV comprising mebendazole.
  • the composition may be provided in a dosage form comprising approximately 350mg mebendazole for administering to persons aged 6 to 18 years and 450mg mebendazole for administering to persons aged 18 years and older.
  • the dosage form may be in the form of one of pressed tablet form, capsule form, vaccine form and syrup form.
  • a dosage form for use in a method of reducing an HIV viral load in a subject infected with HIV the dosage form comprising mebendazole.
  • the dosage form may comprise 50mg to 800mg mebendazole for administering to persons aged 6 to 18 years. More specifically, the dosage form may comprise about 350mg mebendazole.
  • the dosage form may comprise 50mg to 1 OOOmg mebendazole for administering to persons aged 18 years and older. More specifically, the dosage form may comprise about 450mg mebendazole for administering to persons aged 18 years and older.
  • the dosage form may be in the form of one of a pressed tablet, a vaccine form, a capsule form or a syrup form for oral administration.
  • mebendazole in the manufacture of a medicament for treating a subject infected with HIV.
  • a composition comprising mebendazole in a tablet form for use in a method of reducing an HIV viral load in a human subject infected with HIV (HIV-1 ).
  • the tablet is produced by providing the mebendazole in powder form, then mixing the mebendazole together with an excipient binding agent and moulding the mixed ingredients under pressure to form a pressed tablet.
  • the composition may be provided in vaccine form or in capsule form or in syrup form for oral administration.
  • the composition comprises 350mg mebendazole for administering to persons aged 6 to 1 8 years.
  • the composition comprises 450mg mebendazole for administering to persons of 18 years and older.
  • the composition is used in a method of reducing an HIV viral load in a human subject infected with HIV, by administering an oral dose of the composition to the subject.
  • Mebendazole is a known anthelminthic and the chemical formula and efficacy as an anthelminthic of mebendazole is described hereinafter.
  • Mebendazole, lUPAC name: [(5-Benzoyl-1 H-benzimidazol-2-yl) carbamic acid methyl ester] is an anthelminthic effective against threadworms (Enterobius), round worms (Ascaris), whipworms (Tricharis) and hook worms (Ancylostems and Necator). It is also effective against tapeworms and strangyloid worms.
  • helminthic infections are believed to significantly suppress the immune mechanisms of the human body thereby further compromising the immune systems of subjects with already compromised immune systems.
  • Such helminthic infections are particularly prevalent in developing countries in which large numbers of people live under poor living conditions and sanitation and where poor nutrition, poverty and lack of education are further contributing factors to the relatively high incidence of helminthic infections.
  • the composition as a defined and described hereinabove is thus specifically intended for use as complementary medicament in the treatment of subjects with compromised immune systems and more specifically in the treatment of subjects infected with HIV-1 .
  • the applicant believes that the composition is effective in reducing an HIV viral load in a human subject infected with HIV-1 .
  • mebendazole has anti-viral properties and is effective in reducing an HIV viral load in a human subject infected with HIV (HIV-1 ), when administered orally to the patient.
  • the invention extends to a dosage form of the composition for use in a method of reducing an HIV viral load in a human subject infected with HIV (HIV-1 ).
  • the dosage form for administering to persons aged 6 to 18 years may comprise 50mg to 800mg mebendazole and more specifically, about 250mg mebendazole.
  • the dosage form for administering to persons aged 18 years and older may comprise 50mg to 1 OOOmg mebendazole and more specifically, about 450mg mebendazole.
  • the invention extends yet further to a pharmaceutical composition comprising mebendazole in the amounts referred to above for use in a method of reducing an HIV viral load in a subject infected with HIV (HIV-1 ).
  • the invention also extends to the use of mebendazole in the manufacture of a medicament for treating a subject infected with HIV.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition et une forme posologique comprenant du mébendazole pour utilisation dans un procédé de réduction de la charge virale en VIH chez un sujet infecté par le VIH. Cette forme posologique est destinée à une administration par voie orale et renferme environ 350 mg de mébendazole pour l'administration à des personnes de 6 à 18 ans et environ 450 mg de mébendazole pour l'administration à des personnes de 18 ans et plus. Le mébendazole, en plus d'être un médicament anthelmintique, présente des propriétés antivirales, ce qui le rend efficace pour réduire la charge virale en VIH chez un sujet infecté par le VIH-1.
PCT/IB2017/050676 2016-02-16 2017-02-08 Composition et forme posologique pour réduction de la charge virale en vih WO2017141137A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2016/01033 2016-02-16
ZA201601033 2016-02-16

Publications (1)

Publication Number Publication Date
WO2017141137A1 true WO2017141137A1 (fr) 2017-08-24

Family

ID=59625713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/050676 WO2017141137A1 (fr) 2016-02-16 2017-02-08 Composition et forme posologique pour réduction de la charge virale en vih

Country Status (1)

Country Link
WO (1) WO2017141137A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204318A3 (fr) * 2020-11-02 2022-12-15 Skymount Medical Us Inc. Utilisation de mébendazole pour le traitement d'une infection virale
GB2608865A (en) * 2021-07-19 2023-01-18 Al Ahliyya Amman Univ Therapeutic

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036747A2 (fr) * 2006-09-21 2008-03-27 Amarillo Biosciences, Inc. Composition et procédé d'immunomodulation
WO2010041097A1 (fr) * 2008-10-08 2010-04-15 De Felice Giancarlo Nouveaux adjuvants de vaccin
WO2013093790A1 (fr) * 2011-12-22 2013-06-27 Shoket Latief Composition pour réduire une charge virale de vih comprenant du praziquantel, du niclosamide et de l'albendazole
WO2015051035A1 (fr) * 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systèmes et procédés pour le criblage de médicament de bruit d'expression génétique et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036747A2 (fr) * 2006-09-21 2008-03-27 Amarillo Biosciences, Inc. Composition et procédé d'immunomodulation
WO2010041097A1 (fr) * 2008-10-08 2010-04-15 De Felice Giancarlo Nouveaux adjuvants de vaccin
WO2013093790A1 (fr) * 2011-12-22 2013-06-27 Shoket Latief Composition pour réduire une charge virale de vih comprenant du praziquantel, du niclosamide et de l'albendazole
WO2015051035A1 (fr) * 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systèmes et procédés pour le criblage de médicament de bruit d'expression génétique et leurs utilisations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204318A3 (fr) * 2020-11-02 2022-12-15 Skymount Medical Us Inc. Utilisation de mébendazole pour le traitement d'une infection virale
GB2608865A (en) * 2021-07-19 2023-01-18 Al Ahliyya Amman Univ Therapeutic

Similar Documents

Publication Publication Date Title
JP6122639B2 (ja) インテグラーゼ阻害剤を含有する固形医薬組成物
JP2019517542A5 (fr)
JP2017526697A5 (fr)
WO2013034927A8 (fr) Compositions à base de lopinavir et de ritonavir
WO2017222903A1 (fr) Système d'administration de médicaments pour l'administration d'agents antiviraux
WO2017141137A1 (fr) Composition et forme posologique pour réduction de la charge virale en vih
JP2017514911A5 (fr)
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
JP2016512247A5 (fr)
JP5624472B2 (ja) ロペラミド塩酸塩含有フィルム製剤
MX2019001032A (es) Formulacion que tiene caracteristicas mejoradas de liberacion de farmacos ph dependientes, que contienen esomeprazol o una de sus sales farmaceuticas aceptable.
WO2018191093A1 (fr) Système d'administration de médicament pour l'administration d'agents antiviraux
MX2021009877A (es) Extracto liquido de cera aleda, su formulacion y uso del mismo.
JP2020525459A5 (fr)
WO2017141136A1 (fr) Composition et forme posologique pour réduction de la charge virale en vih
WO2013093790A1 (fr) Composition pour réduire une charge virale de vih comprenant du praziquantel, du niclosamide et de l'albendazole
WO2009118706A2 (fr) Traitement d’infections helminthiques
Mahesh et al. Formulation and evaluation of fast dissolving tablet of prasugrel
GB2470494A (en) Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
TWI612968B (zh) 南洋山蘇水萃物的用途
CN101732301A (zh) 绿原酸在制备防治老年性痴呆的药中的应用
JP6830482B2 (ja) 粘膜病変の治療のための配合物
US20190183956A1 (en) Use of a clove oil fraction
TW201907938A (zh) 南洋山蘇水萃物的用途
Tejaswi et al. An overview on anti-retroviral drugs: A review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17752752

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17752752

Country of ref document: EP

Kind code of ref document: A1